{
}
Speculation about a potential merger between insurers Baloise and Helvetia has resurfaced, driven by major shareholder Cevian's influence. While Baloise shares have underperformed compared to Helvetia, analysts consider the merger scenario unlikely despite its intriguing nature. In financial markets, the US dollar strengthened against major currencies ahead of the Fed's interest rate decision, while oil prices fell due to rising US reserves. The SMI index struggled near the 13,000-point mark as investors awaited key interest rate announcements from both the Fed and the Swiss National Bank.
Roche is projected to lead the pharmaceutical industry in sales by 2025, despite not having any products in the top drug rankings. Eli Lilly and Novo Nordisk are expected to rise in the rankings, with combined sales from their GLP-1 drugs surpassing $70 billion this year. Meanwhile, Pfizer is anticipated to drop from fifth to ninth place, while Merck & Co. and AbbVie are expected to secure the second and third spots, respectively.
Novartis is closing MorphoSys sites in Munich and Boston, resulting in approximately 330 layoffs, as part of its integration strategy following the €2.7 billion acquisition earlier this year. The decision aligns with a focus on prioritizing R&D programs, particularly the delayed approval pathway for the oncology candidate pelabresib. This trend of post-acquisition job cuts has been observed across several major pharma companies in recent years.
Roche has received EU approval for a prefilled syringe (PFS) of its ophthalmology drug Vabysmo, designed to treat neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This PFS offers a convenient administration method for over 9 million affected individuals in the EU and is the first of its kind containing a bispecific antibody for these conditions. Following strong sales growth, the approval is expected to further enhance Roche's revenue amid increasing competition in the ophthalmology market.
AbbVie's schizophrenia drug emraclidine failed two mid-phase trials, performing no better than placebo, resulting in a $40 billion market cap loss for the company. This setback follows the recent approval of Bristol Myers Squibb's Cobenfy, the first new schizophrenia drug in decades, which boosted BMS's share price by 12%. The failure raises concerns for other companies developing similar drugs in the same class.
Gilead Sciences has appointed Dietmar Berger, M.D., Ph.D., as its new chief medical officer, recruiting him from Sanofi to replace Merdad Parsey. Berger, a cancer specialist with extensive experience at Genentech and Sanofi, will oversee Gilead's oncology pipeline, which is crucial for the company's growth strategy. He is set to start on January 2, 2024, as Gilead aims to enhance its oncology business amid significant clinical developments.
ICER's annual report criticizes major pharmaceutical companies, including Gilead, J&J, and Novartis, for "unsupported" price increases on ten drugs, leading to an additional $815 million in U.S. payer costs last year. Gilead's Biktarvy topped the list with a 5.9% hike, costing $359 million. Companies have pushed back, claiming ICER's methodology overlooks crucial clinical evidence and could hinder the development of new treatments.
Gilead Sciences has received several price target increases from analysts, with Oppenheimer and JPMorgan raising their targets to $105, while BMO Capital Markets set theirs at $102. Despite a "Moderate Buy" rating, top analysts favor five other stocks over Gilead. Insider trading activity shows significant sales, with insiders offloading over 63,000 shares in the past ninety days.
Gilead Sciences, Inc. focuses on developing, manufacturing, and marketing therapeutic products, with 98.9% of net sales coming from pharmaceuticals. Key revenue sources include treatments for HIV (63%), COVID-19 (20.4%), and hepatitis viruses. Geographically, 69.2% of sales are in the U.S., followed by Europe (16.4%) and other regions (14.4%).
The North America oncology drugs market, valued at USD 10.13 billion in 2023, is projected to grow at a CAGR of 10.38%, reaching USD 27.20 billion by 2033. Key drivers include advances in cancer research, rising cancer prevalence, and increasing demand for personalized medicine, while challenges include high drug costs and stringent regulations. The market is segmented into cytotoxic, targeted, and hormonal drugs, with targeted therapies expected to dominate due to their effectiveness and reduced toxicity.
Gilead Sciences, Inc.
Companies
| Symbol | GILD |
| Name | Gilead Sciences, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | Foster City |
| Zipcode | 94404 |
| Website | http://www.gilead.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
global markets react to us interest rate signals and mixed earnings reports
Euro
Swiss Franc
United States Dollar
Alphabet Inc.
Gilead Sciences, Inc.
Amazon.com, Inc.
NVIDIA Corporation
Boeing Co
Microsoft Corporation
Apple Inc.
Tesla, Inc.
The Mosaic Co
Elon Musk
Donald Trump
Jerome Powell
Brian West
Vladimir Putin
Show more
05:11 20.03.2025
roche set to lead global pharma sales in 2025 as rivals rise
United States Dollar
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
ABBVIE
Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca PLC
Gilead Sciences, Inc.
GSK plc
Eli Lilly and Co
Johnson & Johnson
Novo Nordisk A/S
Robert F. Kennedy Jr.
Show more
19:07 03.01.2025
Novartis to close MorphoSys sites and lay off 330 employees
Euro
Sanofi
GSK plc
Gilead Sciences, Inc.
Incyte Corp
Novartis AG
Immunomedics Inc.
Horizon Therapeutics Public Lim
Bellus Health Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Co
Amgen Inc.
MorphoSys AG
USA
DEU
CHE
Vas Narasimhan
Show more
15:47 19.12.2024
Roche secures EU approval for Vabysmo prefilled syringe for retinal diseases
Swiss Franc
Bristol-Myers Squibb Co
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
Gilead Sciences, Inc.
CHE
Show more
19:40 16.12.2024
setbacks in drug development impact schizophrenia and oncology markets
Arcus Biosciences, Inc.
Hoffmann-La Roche AG
Gilead Sciences, Inc.
Biohaven Ltd.
Merck & Co., Inc.
Genentech
Cassava Sciences, Inc.
ABBVIE
Bristol-Myers Squibb Co
BioAge Labs, Inc.
USA
Jean Rochefort
Show more
01:00 16.12.2024
gilead appoints dietmar berger as new chief medical officer from sanofi
United States Dollar
Hoffmann-La Roche AG
Gilead Sciences, Inc.
Bayer AG
Immunomedics Inc.
Genentech
Amgen Inc.
Sanofi
USA
FRA
John S. Reed
Houman Ashrafian
Daniel O'Day
Merdad Parsey
Dietmar Berger
Show more
11:20 13.12.2024
icER highlights unsupported price hikes by major pharmaceutical companies
United States Dollar
Johnson & Johnson
Exelixis, Inc.
Gilead Sciences, Inc.
Pfizer Inc.
Novartis AG
USA
Show more
20:24 12.12.2024
gilead sciences receives mixed analyst ratings and insider selling raises concerns
14:22 28.11.2024
Gilead Sciences reports strong pharmaceutical sales driven by HIV and COVID-19 treatments
21:07 22.11.2024
rth america oncology drugs market projected to reach 27.20 billion by 2033
United States Dollar
Novartis AG
Gilead Sciences, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Johnson & Johnson
Amgen Inc.
Bristol-Myers Squibb Company
Biogen Inc.
AstraZeneca PLC
Roche Holding AG
Pfizer Inc.
Merck & Co., Inc.
Celgene Corporation
AbbVie Inc.
Eli Lilly and Company
USA
Show more
14:29 22.11.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Domestic Politics
Banking Regulations
Global Financial Events
CEO Changes
Government Policies
Retail and Consumer Goods
Workplace Trends
Elections & Campaigns
Market Analysis and Predictions
Central Bank Actions
Global Trade Developments
Startups & Entrepreneurship
Hedge Funds & Private Equity
Banking & Investment Regulations
Corporate Social Responsibility
Countries:
Companies:
Tesla, Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Deutsche Bank Money Market PP
JPMorgan Chase & Co.
Barclays PLC
Credit Suisse Strategic Income I
Apple Inc.
CREDIT AGRICOLE
SpaceXCoin USD
Lloyds Banking Group plc
BNP Paribas SA
Amazon.com, Inc.
The Goldman Sachs Group, Inc.
UBS Group AG
Credit Agricole
Banco Santander, S.A.
Reinsurance Group of America, Incorporated
Amundi S.A.
Commerzbank AG
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Offshore Chinese Yuan
Hong Kong Dollar
Norwegian Krone
Filipino Peso
Canadian Dollar
Singapore Dollar
Australian Dollar
Danish Krone
Swedish Krona
Mexican Peso
Qatari Riyal
South African Rand
People: